Cancer Related Major Depression Treated With a Single Dose of Psilocybin
The goal of this randomized placebo controlled trial is to compare the antidepressant effect of a single oral dose of psilocybin 25 mg compared to 1 mg in 100 patients with cancer related major depressive disorder. The main question it aims to answer is:

The primary objective of this study is to evaluate the efficacy of a single 25 mg oral dose of psilocybin for major depressive disorder (MDD) compared to an active placebo (psilocybin 1 mg) assessed as the difference between groups in changes in depressive symptoms, in the following Population: 20-80 (inclusive) years old, current depressive episode (according to Patient Health Questionnaire (PHQ-9)

≥10), \>1 month after cancer diagnosis, with at least 12 months of life expectancy, willingness to abstain from other psychotherapeutic or antidepressant treatments during the study (wash out time 5 half-lives).
MDD
DRUG: psilocybin 25 mg sod|DRUG: psilocybin 1 mg sod
MADRS at day 42, Montgomery Asberg Depression Rating Scale (MADRS) total score (0-60, smaller equals better), day 42
MADRS day 8, Montgomery Asberg Depression Rating Scale (MADRS) total score (0-60, smaller equals better), day 8|MADRS-S at all evaluations between Day 0 and Day 42 (Mixed Models for Repeated Measures (MMRM) x1), Montgomery Asberg Depression Rating Scale self rating (MADRS-S) (0-54, smaller equals better), Day 42|SDS at Day 42, Sheehan Disability Scale (SDS) (0-10, smaller equals better), Day 42|CGI at Day 8 and Day 42 (analysis of covariance (ANCOVA) x6), Clinical Global Impression (CGI), (1-7, smaller equals better), Day 8 and 42|EQ-5D-5L at Day 8 and Day 42 (ANCOVA x6), Euroquol 5 Dimension scale (EQ5D-5L), 0-1, higher equals better, Day 8 and 42|AQOL-6D at Day 42 (ANCOVA x1), Assessing Quality of Life 6 dimensions (AQOL-6D) (0-99, smaller equals better), Day 42|MADRS at Day 90 and Day 180 (ANCOVA x2), Montgomery Asberg Depression Rating Scale (MADRS) total score (0-60, smaller equals better), Day 90 and Day 180|MADRS-S at all evaluations between Day 43 and Day 180 (MMRM x1), Montgomery Asberg Depression Rating Scale self rating (MADRS-S) (0-54, smaller equals better), between Day 43 and Day 180|SDS at Day 180 (ANCOVA x3), Sheehan Disability Scale (SDS) (0-10, smaller equals better), Day 180|GAD-7 at Day 180 (ANCOVA x3), General Anxiety Disorder 7 (GAD-7) (0-21, lower equals better), Day 180|HADS at Day 180 (ANCOVA x3), Hospital Anxiety and Depression Scale (HADS) (0-42, smaller equals better), Day 180|CGI at Day 90 and Day 180 (ANCOVA x6), Clinical Global Impression (CGI), (1-7, smaller equals better), Day 90 and Day 180|EQ-5D-5L at Day 90 and Day 180 (ANCOVA x6), Euroqol 5 Dimension scale (EQ5D-5L), 0-1, higher equals better, Day 90 and Day 180|AQOL-6D at Day 90 and Day 180 (ANCOVA x2), Assessing Quality of Life 6 dimensions (AQOL-6D) (0-99, smaller equals better), Day 90 and Day 180|GAD-7 at Day 42, General Anxiety Disorder 7 (GAD-7) (0-21, lower equals better), Day 42|HADS at Day 42, Hospital Anxiety and Depression Scale (HADS) (0-42, smaller equals better), Day 42
The goal of this randomized placebo controlled trial is to compare the antidepressant effect of a single oral dose of psilocybin 25 mg compared to 1 mg in 100 patients with cancer related major depressive disorder. The main question it aims to answer is:

The primary objective of this study is to evaluate the efficacy of a single 25 mg oral dose of psilocybin for major depressive disorder (MDD) compared to an active placebo (psilocybin 1 mg) assessed as the difference between groups in changes in depressive symptoms, in the following Population: 20-80 (inclusive) years old, current depressive episode (according to Patient Health Questionnaire (PHQ-9)

≥10), \>1 month after cancer diagnosis, with at least 12 months of life expectancy, willingness to abstain from other psychotherapeutic or antidepressant treatments during the study (wash out time 5 half-lives).